Claims for Patent: 9,522,146

Summary for Patent: 9,522,146

Title:	Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
Abstract:	Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
Inventor(s):	Ren; Pingda (San Diego, CA), Liu; Yi (San Diego, CA), Wilson; Troy Edward (San Marino, CA), Li; Liansheng (San Diego, CA), Chan; Katrina (Fremont, CA), Rommel; Christian (La Jolla, CA)
Assignee:	Intellikine LLC (La Jolla, CA)
Application Number:	14/884,612
Patent Claims:	1. A method of treating a disease or disorder for therapeutic benefit in a subject having the disease or disorder, comprising administering to the subject an effective amount of a compound of Formula I-1: ##STR00721## or a pharmaceutically acceptable salt thereof, wherein B is a moiety of Formula II: ##STR00722## wherein W.sub.c is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl, and q is an integer of 0, 1, 2, 3, or 4; X is absent or --(CH(R.sup.9)).sub.z--, and z is an integer of 1; Y is absent or --N(R.sup.9)--; W.sub.d is ##STR00723## R.sup.a' is hydrogen, halo, phosphate, urea, carbonate, unsubstituted or substituted amino, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroalkyl, or unsubstituted or substituted heterocycloalkyl; R.sup.1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amido, alkoxycarbonyl, sulfonamido, halo, cyano, or nitro; each instance of R.sup.2 is independently alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heteroarylalkyl, alkoxy, amino, halo, cyano, hydroxy, or nitro; R.sup.3 is hydrogen, alkyl, or halo; each R.sup.9 is independently hydrogen, alkyl, or heterocycloalkyl; and R.sup.12 is H, unsubstituted or substituted alkyl, cyano, unsubstituted or substituted alkynyl, unsubstituted or substituted alkenyl, halo, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted amino, carboxylic acid, unsubstituted or substituted alkoxycarbonyl, unsubstituted or substituted amido, unsubstituted or substituted acyl, or unsubstituted or substituted sulfonamido; wherein the disease or disorder is leukemia, lymphoma, lupus, or arthritis. 2. The method of claim 1, wherein the compound of Formula I-1 is selected from: ##STR00724## 3. The method of claim 1, wherein W.sub.d is selected from: ##STR00725## 4. The method of claim 1, wherein --X--Y--W.sub.d is selected from: ##STR00726## ##STR00727## 5. The method of claim 1, wherein R.sup.12 is selected from hydrogen, cyano, halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, and unsubstituted or substituted alkenyl. 6. The method of claim 1, wherein R.sup.12 is selected from unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocycloalkyl, and unsubstituted or substituted cycloalkyl. 7. The method of claim 1, wherein R.sup.12 is selected from unsubstituted or substituted amido, carboxylic acid, unsubstituted or substituted alkoxycarbonyl, unsubstituted or substituted acyl, and unsubstituted or substituted sulfonamido. 8. The method of claim 1, wherein R.sup.3 is alkyl. 9. The method of claim 8, wherein R.sup.3 is methyl. 10. The method of claim 1, wherein R.sup.3 is halo. 11. The method of claim 10, wherein R.sup.3 is chloro. 12. The method of claim 1, wherein the compound is: ##STR00728## ##STR00729## ##STR00730## or a pharmaceutically acceptable salt thereof. 13. The method of claim 1, wherein the compound is: ##STR00731## ##STR00732## ##STR00733## or a pharmaceutically acceptable salt thereof. 14. The method of claim 1, wherein the compound is: ##STR00734## ##STR00735## or a pharmaceutically acceptable salt thereof. 15. The method of claim 1, wherein the compound is: ##STR00736## ##STR00737## or a pharmaceutically acceptable salt thereof. 16. The method of claim 1, wherein the disease or disorder is leukemia or lymphoma. 17. The method of claim 16, wherein the disease or disorder is acute lymphocytic leukemia, hairy cell leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), or chronic neutrophilic leukemia (CNL). 18. The method of claim 16, wherein the disease or disorder is AIDS-related lymphoma, Hodgkin lymphoma, or non-Hodgkin lymphomas. 19. The method of claim 1, wherein the disease or disorder is lupus or arthritis. 20. The method of claim 1, further comprising administering radiation therapy or one or more therapeutic agents. 21. The method of claim 16, wherein the disease or disorder is B-lineage acute lymphoblastic leukemia (B-ALL), T-lineage acute lymphoblastic leukemia (T-ALL), prolymphocytic leukemia (PLL), large granular lymphocytic leukemia (LGF), diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, peripheral T cell lymphomas (PTCL), follicular lymphoma, mantle cell lymphoma, or Waldenstrom's macroglobulinemia. 22. The method of claim 16, wherein the disease or disorder is T-cell leukemia, adult T-cell lymphoma, or cutaneous T-cell lymphoma (CTCL). 23. The method of claim 20, wherein the therapeutic agent is an anti CD20 antibody. 24. The method of claim 20, wherein the therapeutic agent is rituximab, fludarabine, cyclophosphamide, bortezomib, gemcitabine, or dexamethasone, or a mixture thereof.

Details for Patent 9,522,146

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2029-07-15
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2029-07-15
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2029-07-15